zanubrutinib
Sponsor Beone Medicines LTD. · listed as ONC
zanubrutinib is a drug asset sponsored by Beone Medicines LTD., listed as ONC. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 31, 2026 (day precision, medium confidence), tied to trial NCT04170283. That trial is in Phase 3 and currently active not recruiting, studying B-cell Malignancies. It appears across 9 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for zanubrutinib in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT03336333 | Phase 3 | Active, not recruiting | 2021-05-07 | Experimental | BeiGene | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
| NCT04002297 | Phase 3 | Active, not recruiting | 2026-04-27 | Experimental | BeOne Medicines | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma |
| NCT04170283 catalyst | Phase 3 | Active, not recruiting | 2026-12-31 | Experimental | BeOne Medicines | B-cell Malignancies |
| NCT04662255 | Phase 3 | Active, not recruiting | 2027-11 | Active comparator | Loxo Oncology, Inc. | Lymphoma, Mantle-Cell |
| NCT05100862 | Phase 3 | Active, not recruiting | 2028-07 | Experimental | BeOne Medicines | Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma |
| NCT06742996 | Phase 3 | Recruiting | 2028-08-31 | Experimental | BeOne Medicines | Mantle Cell Lymphoma; B Cell Lymphoma |
| NCT07277231 | Phase 3 | Recruiting | 2031-02 | Experimental | BeOne Medicines | Chronic Lymphocytic Leukemia |
| NCT07377578 | Phase 3 | Recruiting | 2031-05-30 | Active comparator | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma |
| NCT06073821 | Phase 3 | Active, not recruiting | 2032-02 | Experimental | BeOne Medicines | CLL |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More ONC catalysts